US · Healthcare · Biotechnology
EPS came in at -0.28 against a street estimate of -0.38 — a beat of 26.3%.
Analysts rate UroGen Pharma Ltd a buy (6 buy, 2 hold, 0 sell out of 8) with an average price target of $60.00.
CONFIDENT ZUSDURI Q2 revenue $50.4M (+73% QoQ) vastly outpaced linear expectations. 1,444 activated sites, 452 unique prescribers, 45% repeat utilization. Company raised FY26 opex guidance but reaffirmed path to profitability with current capital. Q2 2026 No geographic breakdown provided. Analysts pressed on community practice dynamics, acceleration sustainability, and competitive positioning in high-grade disease. Management cautioned against over-extrapolating Q2, emphasized linear adoption curve and physician experience-driven demand, and highlighted 103's safety/ease-of-use advantage vs chemotherapy. 2026-08-05…
Full summary in the app.
| Fund | Stake |
|---|---|
| RTW INVESTMENTS, LLC | 9.30% |
| BlackRock Inc | 5.82% |
| The Toronto-Dominion Bank | 5.35% |
| Morgan Stanley - Brokerage Accounts | 5.24% |
| Kynam Capital Management, LP | 4.98% |
| Jefferies Financial Group Inc | 4.50% |
| American Century Companies Inc | 3.45% |
| SG Americas Securities, LLC | 3.39% |
| Document | Date |
|---|---|
| Company announcement · Q3 2026 UROGEN PHARMA LTD. - 8-K SUMMARY HEADLINE NUMBERS • Company entered into Option and Research License Agreement with IntraGel Therapeutics, Ltd. on A | 2026-08-20 |
| Quarterly report · Q2 2026 UROGEN PHARMA LTD. – 10-Q SUMMARY (Q2 2026) HEADLINE NUMBERS • Cash Position: $79.1 million in cash and cash equivalents; $28.8 million in marketabl | 2026-08-05 |
| Results announced · Q3 2026 UROGEN PHARMA LTD. — Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • ZUSDURI Q2 2026 revenue: $50.4 million, up 73% quarter-over-quarter • Total Q2 202 | 2026-08-05 |
| Board / officer change · Q2 2026 UROGEN PHARMA LTD. - 8-K SUMMARY (JUNE 22, 2026) BUSINESS & SEGMENT HIGHLIGHTS • Company held 2026 Annual Meeting of Shareholders on June 22, 2026 • | 2026-06-23 |
| Company announcement · Q2 2026 UROGEN PHARMA LTD. - 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • UroGen Pharma Ltd. entered into a settlement and license agreement with Teva Pharma | 2026-06-02 |
| Quarterly report · Q1 2026 UROGEN PHARMA LTD. — Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Revenue: $50.959 million (Q1 2026) vs. $20.254 million (Q1 2025) — 151% increase year-o | 2026-05-06 |
| Proxy statement · Q4 2025 UROGEN PHARMA LTD. — 2026 PROXY STATEMENT SUMMARY --- WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Elect seven board members: Arie Belldegrun, M.D | 2026-04-30 |
| Annual report FY2025 UROGEN PHARMA LTD. – 10-K SUMMARY (Year Ended December 31, 2025) HEADLINE NUMBERS • Company: Israel-based biotechnology firm, incorporated in Israel | 2026-03-02 |
Readable in the app.
| Announcement | Date |
|---|---|
| Obtains exclusive options to license IntraGel's SRGel platform technology UroGen Pharma announced on August 18, 2026 that it entered into an Option and Research License Agreement with IntraGel Therapeutics, an Israeli company. Through this deal, UroGen obtained th | 2026-08-20 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for UroGen Pharma Ltd — free to start.
Google PlayApp StoreData updated 2026-09-18.